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Abstract. 
 
Tumor necrosis factor (TNF) and lympho-
 
toxin (LT) 
 
a
 
 are structurally and functionally related 
cytokines. We expressed the TNF and LT-
 
a
 
 genes in 
murine fibrosarcoma L929r2 cells, which can be sensi-
tized to TNF/LT-
 
a
 
—dependent necrosis by inhibitors of 
transcription or translation. Autocrine production of 
murine TNF in L929r2 cells completely downmodu-
lated the expression of the 55- and 75-kD TNF recep-
tors, resulting in resistance to TNF/LT-
 
a
 
 cytotoxicity. 
Partial downmodulation of the 55-kD receptor was ob-
served in human TNF-producing L929r2 cells. In con-
trast, an unaltered TNF receptor expression was found 
on LT-
 
a
 
 L929r2 transfectants. Hence, although similar 
cytotoxic effects are induced by extracellularly adminis-
tered TNF and LT-
 
a
 
, endogenous expression of these 
cytokines fundamentally differs in the way they modu-
late TNF receptor expression. Unlike LT-
 
a
 
, secreted by 
the classical pathway, TNF is first formed as a mem-
brane-bound protein, which is responsible for receptor 
downmodulation. To explore whether the different 
pathways for secretion of TNF and LT-
 
a
 
 explain this 
difference, we examined the effect of membrane-bound 
LT-
 
a
 
 expression. This was obtained by exchange of the 
classical signal sequence of LT-
 
a
 
 for the membrane an-
chor of chicken hepatic lectin. Membrane retention of 
LT-
 
a
 
 resulted indeed in receptor downmodulation and 
TNF/LT-
 
a
 
 resistance. We conclude that membrane re-
tention of newly synthesized TNF or LT-
 
a
 
 is absolutely 
required for receptor downmodulation and TNF/LT-
 
a
 
 
resistance.
Key words: tumor necrosis factor ¥ lymphotoxin ¥ cy-
totoxicity ¥ downmodulation ¥ membrane
T
 
umor
 
 necrosis factor (TNF)
 
1
 
 and lymphotoxin (LT) 
 
a
 
are related cytokines with 30% amino acid sequence
identity (Fiers, 1992; Beyaert and Fiers, 1998). The
corresponding genes are closely linked within the class III
region of the major histocompatibility complex (Nedospa-
sov et al., 1986; Spies et al., 1986). Both genes appear to be
independently regulated (Sung et al., 1988; English et al.,
1991). In general, TNF and LT-
 
a
 
 exert similar biological
activities, although both qualitative and quantitative dif-
ferences have been found. LT-
 
a
 
 seems less potent than
TNF in proinflammatory activities, such as activation of
the nuclear factor 
 
k
 
B (Chaturvedi et al., 1994). TNF and
LT-
 
a
 
 regulate the production of interleukin (IL) 6 and
macrophage colony-stimulating factor in fibroblast cells
differently (Akashi et al., 1989; Mantovani et al., 1990). In
contrast to TNF, LT-
 
a
 
 acts as a growth factor for some B
cell lines transformed by Epstein-Barr virus (Estrov et al.,
1993). It was also reported that TNF but not LT-
 
a
 
 could
directly induce lysis of trypanosomes (Lucas et al., 1994).
Macrophages are the major cellular source of TNF (Mat-
thews et al., 1982), but several other cell types have been
reported to produce TNF as well, including lymphocytes,
fibroblasts, neutrophils, endothelial cells, and several tu-
mor cell lines (Vil ek and Lee, 1991). LT-
 
a
 
 production
seems to be restricted to T- and B-lymphocytes (Paul and
Ruddle, 1988). Remarkably, TNF and LT-
 
a
 
 exert their bi-
ological activities through binding to the same set of ubiq-
uitously expressed cell surface receptors. Two types
have been characterized, namely TNF-R55 and TNF-R75,
named according to their relative molecular masses of 55
and 75 kD, respectively. Murine TNF (mTNF) and murine
c•
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mTNF, murine TNF; neo
 
r
 
, neomycin-resistant; TNF, tumor necrosis fac-
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LT-
 
a
 
 bind both human TNF (hTNF)-R55 and hTNF-R75.
In contrast, hTNF and human LT (hLT)-
 
a
 
 bind mTNF-
R55 but not mTNF-R75 (Tartaglia et al., 1992). Specific
TNF-R55 triggering is known to be responsible for most of
the wide variety of TNF and LT-
 
a
 
 biological effects (En-
gelmann et al., 1990; Espevik et al., 1990; Tartaglia et al.,
 
1993
 
b
 
; Fiers, 1995). The role of TNF-R75 as a direct signal
transducer has so far mainly been documented in T-lym-
phocytes (Tartaglia et al., 1991; Vandenabeele et al., 1992;
Tartaglia et al., 1993
 
a
 
).
TNF and LT-
 
a
 
 are differently processed during biosyn-
thesis. TNF is initially synthesized as a biologically active,
26-kD type-II transmembrane proform consisting of a pre-
sequence, which functions as a membrane anchor, and the
extracellular 17-kD TNF (Mller et al., 1986; Kriegler et al.,
1988). Trimerization occurs already at the proform stage
(Tang et al., 1996) and the 26-kD proform subunits are
then cleaved proteolytically at the cell surface by TNF
convertase, releasing mature, trimeric TNF (Black et al.,
1997; Moss et al., 1997). There are two different genes in
the LT system, encoding LT-
 
a
 
 and LT-
 
b
 
. Secreted LT-
 
a
 
 is
presumably formed in the lumen of the endoplasmic retic-
ulum, where nascent LT-
 
a
 
 polypeptides form homotri-
mers, which then progress through the secretory pathway
(Androlewicz et al., 1992). Surface-bound LT occurs as a
heterotrimeric complex consisting predominantly of one
LT-
 
a
 
 monomer and two membrane-bound LT-
 
b
 
 mole-
cules, the latter serving as a membrane anchor (Browning
et al., 1995). LT-
 
a
 
/LT-
 
b
 
 complex formation presumably
takes place early during biosynthesis via binding of a
secretory LT-
 
a
 
 subunit to membrane-anchored LT-
 
b
 
 (An-
drolewicz et al., 1992). This heteromeric LT-
 
a
 
1
 
b
 
2
 
 complex
does not bind to TNF-R55 or TNF-R75, but specifically in-
teracts with a TNF receptor-related protein, the LT-
 
b
 
 re-
ceptor (Crowe et al., 1994). Signaling via the LT-
 
b
 
 recep-
tor can induce cell death of some human adenocarcinomas
(Browning et al., 1996). It can also activate the NF-
 
k
 
B
transcription factor in some, but not all, LT-
 
b
 
 receptor-pos-
itive cells (Mackay et al., 1996). This LT-
 
a
 
/LT-
 
b
 
 ligand/recep-
tor pair is especially important in lymphoid organogenesis.
Mice lacking LT-
 
a
 
 or LT-
 
b
 
 do not develop peripheral
lymph nodes, splenic germinal centers and PeyerÕs patches
(De Togni et al., 1994; Koni et al., 1997).
Previously, we demonstrated that autocrine TNF pro-
duction induced by transfection of an exogenous TNF
gene rendered TNF-sensitive murine L929s fibrosarcoma
cells resistant to TNF/LT-
 
a
 
—mediated cell lysis. In con-
trast, transfection of the hLT-
 
a
 
 gene did not result in sta-
ble LT-
 
a
 
—producing transfectants (Vanhaesebroeck et al.,
1992). In this paper, we focus on the question why the
closely related LT-
 
a
 
 can apparently not be produced by
cells that are sensitive to the cytotoxic action of TNF/LT.
This is not due to the inability of L929 cells to express LT-
 
a
 
,
since transfection with a genomic hLT-
 
a
 
/hTNF construct
resulted in stable production of both hTNF and hLT-
 
a
 
(Vanhaesebroeck et al., 1992). Therefore, the biological
activities of autocrine LT-
 
a
 
 production were investigated
in more detail, using different types of TNF-resistant de-
rivatives of L929s cells. Our results demonstrate that pre-
existing cellular TNF resistance is essential to allow stable
production of secreted LT-
 
a
 
. This autocrine LT-
 
a
 
 had no
effect on the phenotype of TNF resistance of the produc-
ing cells, and also there was no TNF receptor downmodu-
lation. Next, we investigated whether these observations
could be explained by the fact that LT-
 
a
 
 is not membrane-
bound in the course of its synthesis. Therefore, we exam-
ined the effect of expression of a chimera, in which the
classical signal sequence of LT-
 
a
 
 was exchanged for the
membrane anchor structure of chicken hepatic lectin (CHL),
a type-II trimeric protein. Expression of this CHL.hLT-
 
a
 
now induced receptor downmodulation and TNF/LT-
 
a
 
resistance. Thus, we conclude that the introduction of a
membrane-anchoring step during the biosynthesis of LT-
 
a
 
is sufficient and necessary to mediate an effect similar to
that obtained with autocrine-produced TNF.
 
Materials and Methods
 
Cell Lines and Cell Culture
 
Derivatives of the murine L929s fibrosarcoma cell line were used.
L929sA, a TNF-sensitive subclone derived by limiting dilution, has a very
 
low background of spontaneous TNF-resistant cells (
 
,
 
4 
 
3
 
 10
 
2
 
6
 
 vs. 2 
 
3
 
10
 
2
 
2
 
 for parental L929s cells; Vanhaesebroeck et al., 1992). The TNF-
resistant L929r1.1 and L929r2 derivatives of L929s were obtained by TNF
selection on L929s cells (Vanhaesebroeck et al., 1991). All L929 cell lines
were cultured in DME (Life Technologies, Paisley, UK), supplemented
with 5% newborn calf serum (Life Technologies), 5% FCS (Life Technol-
ogies), and antibiotics. The murine WEHI 164 cl 13 fibrosarcoma cell line
(Espevik and Nissen-Meyer, 1986) was cultured in RPMI 1640, supple-
mented with 10% FCS and antibiotics. All cell lines were repeatedly
found to be 
 
Mycoplasma
 
-free as judged from a DNA fluorochrome assay.
 
Cytokines and Antisera
 
Purified 
 
E. coli
 
-derived recombinant mTNF, hTNF, and hLT-
 
a
 
 were pre-
pared in our laboratory and had a specific activity of 2 
 
3
 
 10
 
8
 
, 8.4 
 
3
 
 10
 
7
 
,
and 3.1 
 
3
 
 10
 
7
 
 IU/mg protein, respectively. International standards for
TNF quantification were obtained from the National Institute for Biologi-
cal Standards and Control (Potters Bar, UK). Polyclonal rabbit antiserum
directed against mTNF, hTNF, or hLT-
 
a
 
 was provided by Mr. J. Van der
Heyden (Roche Research, Ghent, Belgium). Polyclonal rabbit antisera di-
rected against mTNF-R55 and mTNF-R75 were a gift of Dr. W.A. Buur-
man (University of Limburg, Maastricht, The Netherlands).
 
Determination of TNF and LT-
 
a
 
 Bioactivity in Cell 
Culture Supernatant
 
Supernatant of transfected cell lines was 100-fold concentrated using Cen-
triprep-10 and Centricon-10 micro-separation devices (Amicon, Danvers,
MA). TNF or LT-
 
a
 
 were quantified in an 18-h cytotoxicity assay using
WEHI 164 cl 13 cells in the presence of 1 
 
m
 
g/ml actinomycin D (ActD; Es-
 
pevik and Nissen-Meyer, 1986). The detection limit of this assay was 
 
z
 
1
pg TNF or LT-
 
a
 
/ml. Neutralization was performed with rabbit polyclonal
antiserum specific for mTNF, hTNF, or hLT-
 
a
 
.
 
Plasmid Constructions
 
The CHL.hTNF and CHL.hLT-
 
a
 
 fusion genes containing the membrane
anchor structure of CHL (a gift from Dr. K. Drickamer, Columbia Uni-
versity, New York, NY), followed by mature hTNF and hLT-
 
a
 
, respec-
tively, were constructed by fusion PCR (Olsen, 1992) using appropriate
oligonucleotide primers. The PCR products were inserted as an EcoRI-
Not fragment into an EcoRI-Not-opened pSV-SPORT1 vector (Life
Technologies), which contains an E-tag COOH terminally from the in-
serted PCR fragments. The chimeric gene sequences were verified by
DNA sequencing.
 
Expression Vectors and Transfection
 
The pSV23S vector, driving the expression of a gene of interest by the
constitutive SV-40 early promoter, was used in all experiments (Huyle-
broeck et al., 1988). Derived expression vectors were pSV23S-mTNF
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(Fransen et al., 1985), pSV23S-hTNF (Mller et al., 1986), and pSV23S-
hLT-
 
a
 
 (Vanhaesebroeck et al., 1992). The pSV2neo plasmid encoding the
neomycin resistance (neo
 
r
 
) gene under control of the SV-40 early pro-
moter was used as a selection marker (Southern and Berg, 1982). Plasmid
DNA was purified using pZ523 columns (5 Prime 
 
fi 
 
3 Prime, Boulder,
CO). Stable transfection was performed by an improved DNA calcium
phosphate coprecipitation protocol as described (Vanhaesebroeck et al.,
1992).
 
Determination of Cellular Sensitivity to TNF or LT-
 
a
 
TNF/LT-
 
a
 
 sensitivity was determined as described (Vanhaesebroeck et al.,
1991). In brief, cells were seeded in 96-well plates in 0.1 ml of medium at
2
 
 3 
 
10
 
4
 
 or 2,500 cells/well for 18- and 72-h assays, respectively. 12—18 h
later, serial dilutions of TNF or LT-
 
a
 
, alone or in combination with either
ActD (final concentration of 1 
 
m
 
g/ml), cycloheximide (CHX; final concen-
tration of 25 
 
m
 
g/ml), or murine interferon (mIFN)-g (200 IU/ml final con-
centration) were added in 0.1 ml of medium. After an 18-h (for ActD and
CHX) or 72-h (for mIFN-g) incubation period, the surviving cells were
stained with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
and assayed colorimetrically (Tada et al., 1986). The percentage of surviv-
ing cells incubated in the presence of ActD, CHX, or mIFN-g alone was
never lower than 70% (vs. 100% for cells incubated with culture medium
alone).
Flow Fluorocytometry
The presence of mTNF-R55 and mTNF-R75 was determined by incuba-
tion of cells with polyclonal rabbit antiserum against mTNF-R55 or
mTNF-R75 (1 mg antiserum per 4 3 105 cells in 200 ml), followed by incu-
bation with biotinylated donkey anti—rabbit IgG polyclonal antiserum
(Amersham Life Science, Amersham, UK), and treatment with phyco-
erythrin-conjugated streptavidin. All incubations were performed for 1 h
at 48C. Analysis was achieved by flow fluorocytometry using a Coulter
Epics 753 equipped with an argon-ion laser (Coulter, Hialeah, FL). Acidic
treatment to remove soluble TNF or LT-a from the cell surface receptors
was done by incubation of the cells for 3 min at room temperature with
glycine-HCl buffer (50 mM, containing 150 mM NaCl, pH 3.0).
The presence of membrane-bound hTNF or hLT-a was analyzed using
monoclonal mouse antibody directed against the E-tag fused COOH ter-
minally to mature hTNF or hLT-a (see Fig. 1; 1 mg antibody/4 3 105/200 ml;
Pharmacia Biotech, Uppsala, Sweden).
TNF-Binding Assay
TNF was iodinated by using Iodo-Gen (Pierce Chemical Co., Rockford,
IL) to a specific activity of 600 Ci/mmol. Binding studies were performed
on L929r2 cells grown in suspension (Vanhaesebroeck et al., 1991). Cells
were harvested and either untreated or incubated for 5 min at 48C with
glycine-HCl buffer to remove putative receptor-bound, endogenously
produced TNF or hLT-a. Then they were incubated for 4 h at 48C with a
saturating concentration (2 nM) of 125I-hTNF in 200 ml binding buffer
(DME, supplemented with 10% FCS and 0.01% NaN3). Cells were pel-
leted through a naphthalate solution containing a mixture of 1/3 dinonyl
phthalate and 2/3 dibutyl phthalate; the retained radioactivity was deter-
mined in a g-counter. Specific binding of 125I-hTNF was determined by
subtracting the amount of radioactivity bound to the cells in the presence
of a 500-fold excess of unlabeled TNF from the radioactivity in the pres-
ence of 125I-hTNF alone. Aspecific binding of 125I-hTNF was about 15% of
the total binding.
Results
Expression of hLT-a in L929 Derivatives with Different 
TNF-resistant Phenotype
Previously, we demonstrated that in contrast to TNF,
transfection of LT-a in TNF/LT-a—sensitive L929sA cells
does not result in stable LT-a—producing cells (Vanhaese-
broeck et al., 1992). However, transfection of genomic
hLT-a/hTNF in L929s cells led to the production of both
hTNF and hLT-a, excluding the possibility that this cell
type is intrinsically unable to produce functional LT-a
(Vanhaesebroeck et al., 1992). To determine whether co-
expression of TNF or, more likely, TNF/LT-a resistance is
necessary to efficiently express LT-a, we transfected hLT-a
cDNA in TNF-resistant L929s derivatives. L929r1 cells
constitutively produce low levels of TNF and are com-
pletely TNF-resistant, whereas non-TNF-producing L929r2
cells can be sensitized to TNF cytotoxicity by inhibition of
transcription or translation with ActD or CHX, respec-
tively (Vanhaesebroeck et al., 1991). After transfection of
hLT-a cDNA in combination with the neor gene in L929r1
and in L929r2 cells, G418-resistant colonies were obtained
(Table I), which were tested for the production of mTNF
and hLT-a. In L929r1 cells, the cytotoxic activity in the su-
pernatants of cells transfected with neor alone could be
completely neutralized by antiserum against mTNF (Fig. 2
A), whereas antiserum against hLT-a was also required to
completely block the cytotoxic activity of supernatants of
clones obtained after cotransfection with the hLT-a gene
(Fig. 2 B). The cytotoxic activity in supernatants of L929r2
transfectants was completely neutralized by antiserum di-
rected against hLT-a (Fig. 2 C). These results indicate that
both types of TNF-resistant cells can produce hLT-a.
Clearly, efficient hLT-a production does not require TNF
gene expression; a preexisting TNF/LT-a resistance is suf-
ficient for L929 cells to become LT-a producers after
transfection of the LT-a gene.
Figure 1. Overview of chimeric constructs. IC, intracellular do-
main; TM, transmembrane domain; EC, extracellular domain;
NR, neck region.
Table I. Number of L929 Colonies Surviving G418 Selection 
after Transfection with TNF or LT-a Genes
Cell line Genes transfected
Number of G418-resistant
colonies/2 3 105 transfected cells
L929r1.1 neor 115 6 15 (100)*
neor 1 hLT-a 108 6 20 (94)
L929r2 neor 100 6 20 (100)
neor 1 mTNF 125 6 25 (125)
neor 1 hTNF 55 6 15 (55)
neor 1 hLT-a 80 6 10 (80)
*Expressed as mean 6 SD of triplicate culture flasks of four representative experi-
ments. The number of surviving colonies, expressed as percentage of the number of
colonies obtained after transfection with the neor gene alone, is shown in brackets.
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Autocrine LT-a Production Does Not Alter the
TNF-resistant Phenotype
We further analyzed the effect of autocrine production of
TNF and/or LT-a on TNF/LT-a sensitivity. As shown in
Table I, transfection of TNF or hLT-a cDNA did not re-
sult in counterselection, neither in L929r1 nor in L929r2
cells. The TNF/LT-a—resistant phenotype of the L929r1
cell line was not influenced by autocrine hLT-a produc-
tion (data not shown). Expression of mTNF levels (even
minimal ones) in L929r2 cells conferred complete resis-
tance to TNF/LT-a cytotoxicity in the presence of ActD,
CHX, or mIFN-g (Table II; data for CHX and mIFN-g are
not shown). Expression of hTNF induced only partial
TNF/LT-a resistance (Table II), with a level of resistance
proportional to the amount of hTNF produced in the su-
pernatant, a phenomenon also observed in hTNF L929sA
transfectants (Vanhaesebroeck et al., 1992). In contrast,
no alteration in TNF/LT-a susceptibility was observed af-
ter LT-a production, not even by high LT-a production
levels (Table II). So it is clear that the absence of TNF/LT-a
resistance in LT-a—producing cells is not due to lower cy-
tokine expression levels as compared with TNF-producing
cells. This different effect of autocrine TNF vs. LT-a can-
not be explained by a differential sensitivity of production
of these cytokines to a treatment with metabolic blockers
(Table III). ActD or CHX treatment for 18 h was found to
have a similar effect on LT-a and TNF secretion in L929r2
transfectants. ActD treatment (at a concentration used in
standard cytotoxicity assays) resulted in a twofold drop in
cytokine expression levels, whereas treatment with CHX
reduced the cytokine production levels by a factor of 20—
50 (Table III). These observations show that autocrine
LT-a expression, in contrast to TNF, is not capable of
modulating the TNF-resistant/susceptible phenotype of
L929r2 cells.
Figure 2. Cytotoxic activity present in the supernatant of L929r1
cells transfected with neor alone (A), or with neor and hLT-a (B),
as well as in L929r2 cells transfected with neor and hLT-a (C).
Cytotoxicity was tested in the absence (m) or presence of antise-
rum to hLT-a (j), mTNF (h), or hLT-a and mTNF (n).
Table II. TNF/LT-a Sensitivity of L929r2 Cells Transfected with neor Alone, or Combined with TNF or LT-a Genes
Sensitivity toà
Genes transfected Cells analyzed
TNF or LT-a
in supernatant mTNF
hTNF
(72-h assay) hLT-a mTNF
hTNF
(18-h assay 1 ActD) hLT-a
pg/ml*
neor Clone B1 0 .40,000⁄ .40,000 .40,000 18 54 54
Clone B2 0 .40,000 .40,000 .40,000 54 164 164
neor 1 mTNF Clone C1 170 .40,000 .40,000 .40,000 .40,000 .40,000 .40,000
Clone C2 3,700 .40,000 .40,000 .40,000 .40,000 .40,000 .40,000
neor 1 hTNF Clone D1 94 .40,000 .40,000 .40,000 493 4,444 4,444
Clone D2 4,700 .40,000 .40,000 .40,000 20,000 .40,000 .40,000
neor 1 hLT-a Clone E1 300 .40,000 .40,000 .40,000 18 54 54
Clone E2 1,700 .40,000 .40,000 .40,000 54 265 240
*Cytokine production found in 100-fold concentrated supernatant.
àExpressed in U/ml TNF or LT-a needed to obtain 50% cytotoxicity.
⁄.40,000 means that 50% killing was not observed using the indicated TNF/LT-a concentration.
Table III. Cytokine Production in the Supernatant of
L929r2 Transfectants
L929r2 cells transfected with
Amount of mTNF/hTNF/hLT-a produced
after treatment for 18 h with
Ñ 1 mg/ml ActD 25 mg/ml CHX
neor 0* 0 0
neor 1 mTNF 3,797 2,400 (63%) 84 (2%)
neor 1 hTNF 2,400 1,410 (58%) 96 (4%)
neor 1 hLT-a 1,700 854 (50%) 84 (5%)
*IU/ml found in 100-fold concentrated supernatant of L929r2 transfectants. The su-
pernatants were harvested, concentrated and tested in a cytotoxicity assay on WEHI
164 cl 13 cells (percentages in brackets indicate cytokine production as compared to
the amount produced by untreated cells).
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Effect of TNF or LT-a Transfection on TNF-R55 and 
TNF-R75 Expression Levels
Previously, we demonstrated a correlation between the in-
duction of TNF resistance and the downmodulation of
TNF receptors (Vanhaesebroeck et al., 1992). TNF-R55
and TNF-R75 expression in the different L929r2 transfec-
tants was first measured by flow fluorocytometric analysis.
In the fully resistant mTNF-producing L929r2 trans-
fectants, no TNF-R55 or TNF-R75 expression could be
detected (Fig. 3 B). On hTNF L929r2 transfectants, a
downmodulation of TNF-R55 but not of TNF-R75 was ob-
served (Fig. 3, C—D). This downmodulation was propor-
tional to the amount of hTNF production (Fig. 3 C, low
producer; D, high producer). In contrast, hLT-a—produc-
ing L929r2 cells showed no downmodulation of TNF-R55
or TNF-R75 (Fig. 3 E). Despite the apparent absence of
detectable TNF-R55 on some hTNF transfectants, TNF
could still induce cytotoxicity, which is mediated via TNF-
R55 in L929r2 cells (Vercammen et al., 1995). This sug-
gests that low numbers of functional TNF-R55 must be
present on the hTNF-producing cells. To detect these and
to confirm the data obtained with flow cytometric analysis
on the expression levels of TNF-R55, we examined the
presence of specific binding sites for 125I-hTNF (TNF-R55)
on mTNF-, hTNF-, or hLT-a—producing L929r2 transfec-
tants. Specific hTNF binding could be detected on neor
transfectants. This binding disappeared after treatment
with glycine-HCl at pH 3 (Fig. 4), indicating that a low pH
leads to the dissociation of TNF from its receptor. Pre-
treatment with glycine-HCl had no effect on subsequent
hTNF binding, demonstrating that acid pretreatment did
not remove the TNF-R55 molecules from the plasma
membrane or had any adverse side effects. No specific 125I-
hTNF binding could be detected on mTNF transfectants,
even not after pretreatment with glycine-HCl (Fig. 4). This
is in agreement with the absence of receptor molecules
found on mTNF-producing L929sA cells (Vanhaesebroeck
et al., 1992). L929r2 transfectants producing high amounts
of hTNF showed considerably reduced hTNF binding,
which completely disappeared by glycine-HCl treatment
(Fig. 4). Pretreatment of hTNF transfectants with glycine-
HCl could increase 125I-hTNF binding (Fig. 4), indicating
that a fraction of the TNF-R55 molecules on the cell sur-
face was occupied by secreted hTNF. It may be noted that
125I-hTNF binding on hLT-a transfectants was completely
similar to that of neor transfectants (Fig. 4), indicating that
autocrine hLT-a production did not downmodulate TNF-
R55 on the plasma membrane of L929r2 cells. In conclu-
sion, induction of unresponsiveness to TNF/LT-a—medi-
ated cytotoxicity is correlated with downmodulation of the
TNF/LT-a receptor on the cell surface. Moreover, in con-
trast to mTNF and hTNF, hLT-a is not able to mediate
such TNF-R55 downmodulation.
Introduction of a Membrane-anchoring
Step in the Biosynthesis Pathway of hLT-a Induces 
TNF/LT-a Resistance and Downmodulation
of TNF/LT-a Receptor
Since membrane retention of TNF is crucial for downmod-
ulation of TNF receptors and induction of TNF/LT-a re-
sistance (Decoster et al., 1998), the differential effect of
autocrine-produced TNF as compared with LT-a can be
explained by a different pathway of producing mature
TNF and LT-a. Hence, it is possible that if LT-a would be
produced as a membrane-bound form like TNF, it would
Figure 3. Flow cytometric analysis of TNF-R55 and TNF-R75 ex-
pression on L929r2 cells transfected with neor alone (A) or neor
combined with genes encoding mTNF (B), hTNF (C, low pro-
ducer; D, high producer) or hLT-a (E). Cells were treated either
with secondary antibody alone (curve 1) or with antiserum di-
rected against TNF-R55 or TNF-R75 and secondary antibody
(curve 2).
Figure 4. Binding of 125I-hTNF by representative colonies of
L929r2 transfectants. Transfected genes are shown below. Cells
were either untreated (white bars) or treated with acidic glycine-
HCl buffer (black bars), or with glycine-HCl buffer followed by
addition of fresh 125I-hTNF for 4 h at 48C (gray bars).
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also confer receptor downmodulation and TNF/LT-a re-
sistance. To test this hypothesis, we exchanged the classi-
cal signal sequence of LT-a for the membrane anchor
structure of CHL (Mellow et al., 1988); by choosing the
latter instead of the TNF presequence we avoided any
possible specific functional contribution of the TNF prese-
quence. CHL is a trimeric, type II transmembrane liver
glycoprotein (Chiacchia et al., 1984; Steer et al., 1990),
which contains a membrane anchor allowing trimerization
of the extracellular domain. Transfection of L929r2 cells
with the neor gene, combined with the CHL.hLT-a chi-
meric gene (Fig. 1) or with the CHL.hTNF chimeric gene
(used as a control), yielded normal numbers of G418-resis-
tant colonies (data not shown). L929r2 cells transfected
with CHL.hLT-a secreted between 1.25 and 30 IU hLT-a/ml;
in the culture supernatant of CHL.hTNF transfectants be-
tween 1.5 and 14 IU/ml hTNF were detected. Expression
of membrane-bound fusion protein could be revealed via
flow fluorocytometric analysis in CHL.hLT-a as well as in
CHL.hTNF transfectants (Fig. 5). These results clearly
demonstrate that expression of either the CHL.hTNF or
the CHL.hLT-a chimeric gene gives rise to production of a
membrane-bound and secreted form comparable to the
biosynthesis of wild-type TNF. We further analyzed the ef-
fect of autocrine-produced CHL.hLT-a or CHL.hTNF on
TNF/LT-a sensitivity. As shown in Table IV, expression of
these chimeric proteins induced unresponsiveness to the
cytotoxic effect of TNF or hLT-a. This is in contrast to the
effect of autocrine LT-a production and is comparable
with the effect of autocrine-produced hTNF (Table II).
Since induction of TNF/LT-a resistance is correlated with
downmodulation of TNF receptors on the cell surface, we
examined the expression level of receptors on the plasma
membrane of L929r2 transfectants expressing CHL.hTNF
or CHL.hLT-a fusion protein. These transfectants showed
considerably reduced binding of 125I-hTNF (TNF-R55)
compared with neor transfectants (Fig. 6). Pretreatment
with glycine-HCl buffer could increase 125I-hTNF binding
(Fig. 6), indicating that a fraction of the TNF-R55 mole-
cules on the cell surface was occupied by secreted hTNF or
hLT-a. This phenomenon was also observed in hTNF-pro-
ducing L929r2 cells (Fig. 4). As expected, no downregula-
tion of TNF-R75, determined via flow cytometric analysis,
could be revealed on CHL.hTNF or CHL.hLT-a transfec-
tants (data not shown). Taken together, we showed that
membrane retention of hLT-a is crucial and sufficient for
the induction of TNF/LT-a resistance and downmodula-
tion of TNF-R55 on the cell surface. Furthermore, these
results strongly indicate that the differential effect of auto-
crine-produced TNF and LT-a on TNF/LT-a sensitivity
and downmodulation of TNF/LT-a receptors can be ex-
plained by their different way of processing for secretion.
Discussion
Previously, we have demonstrated that after transfection
in TNF/LT-a—sensitive L929s cells, TNF production in-
duces resistance to the cytotoxic effect of both autocrine
Figure 5. Flow cytometric
analysis of expression of mem-
brane-bound fusion protein
on L929r2 transfectants. Cells
were transfected with neor
alone (A), or with neor com-
bined with genes encoding
CHL.hTNF (B) or CHL.hLT-a
(C). Cells were treated with
secondary antibody alone
(dotted line) or with antibody
directed against COOH-ter-
minal E-tag and secondary
antibody (solid line).
Table IV. TNF/LT-a Sensitivity of L929r2 Transfectants
Genes transfected
Sensitivity to*
Cells analyzed mTNF hTNF hLT-a
neor Clone B1 18 54 54
Clone B2 6 18 18
neor 1 CHL.hTNF Clone E1 1,481 4,444 5,000
Clone E2 13,333 .40,000⁄ .40,000
neor 1 CHL.hLT-a Clone F1 4,444 13,333 13,333
Clone F2 20,000 .40,000 .40,000
*Expressed in U/ml TNF or LT-a needed to obtain 50% cytotoxicity (assay in combi-
nation with 1 mg/ml ActD for 18 h).
à.40,000 means that 50% killing was not observed using the indicated TNF/LT-a
concentration.
Figure 6. Binding of 125I-hTNF by representative colonies of
L929r2 transfectants. Transfected genes are shown below. Cells
were either untreated (open bars), or treated with acidic glycine-
HCl buffer (hatched bars), or with glycine-HCl buffer followed
by addition of fresh 125I-hTNF for 4 h at 48C (stippled bars).
Decoster et al. Autocrine TNF but Not LT-a Confers TNF/LT Resistance 2063
and exogenous TNF (Vanhaesebroeck et al., 1992). In
contrast, transfection with the hLT-a cDNA gene did not
allow to isolate clones that produced hLT-a or had be-
come TNF/LT-a resistant. Normally, LT-a expression is
restricted to lymphoid cell types (Paul and Ruddle, 1988).
In the case of human tumor cell lines only those of
lymphoid origin have been demonstrated to express and
secrete LT-a after stimulation, whereas TNF can be
produced by tumor cell lines of both lymphoid and non-
lymphoid origin (Krnke et al., 1987). In this report, we
demonstrate that nonlymphoid L929 murine fibrosarcoma
cells can produce LT-a, but only when these cells are resis-
tant to TNF/LT-a cytotoxicity. Remarkable differences
were found between the effects of autocrine TNF and
LT-a in TNF-resistant L929r2 cells. The latter cells can be
sensitized to the cytotoxic action of TNF/LT-a by addition
of ActD, CHX or mIFN-g. But when tested under these
conditions, autocrine mTNF production prevented the
L929r2 cells to become sensitive. Autocrine hTNF produc-
tion resulted in a partial resistance to TNF and LT-a under
these conditions. In contrast, even high levels of autocrine
hLT-a production did not alter the TNF/LT-a—resistant/
sensitive phenotype after addition of ActD, CHX or mIFN-g.
Since we demonstrated a correlation between induction of
resistance and downmodulation of cell surface receptors
after TNF production in L929s cells (Vanhaesebroeck et
al., 1992; Decoster et al., 1998), we investigated whether
TNF and LT-a differ in their capacity to downmodulate
these receptors on the cell surface. As documented previ-
ously for L929s cells, both receptor types were completely
downmodulated on L929r2 cells after autocrine mTNF pro-
duction. hTNF and hLT-a L929r2 transfectants showed an
unaltered expression level of TNF-R75 on their cell sur-
face. This is in agreement with data indicating that hTNF
and hLT-a only interact with mTNF-R55 (Lewis et al.,
1991). Whereas hTNF transfectants showed considerable
downmodulation of TNF-R55, autocrine hLT-a produc-
tion had no effect on TNF-R55 expression levels. A possi-
ble lower binding affinity of hLT-a for mTNF-R55 might
explain the inability of hLT-a to downregulate TNF-R55.
However, this is very unlikely, since hLT-a seems to com-
pete better than hTNF with 125I-hTNF for binding on L929
cells (Browning and Ribolini, 1989). Moreover, hLT-a
shows even a higher binding affinity than hTNF for bind-
ing on L929 cells (Hass et al., 1985; Vanhaesebroeck et al.,
1992). A more likely hypothesis is that the different bio-
synthesis pathways of TNF and LT-a are at the basis of
our observation. TNF is initially synthesized as a trans-
membrane TNF proform, which is then proteolytically
cleaved at the cell surface, releasing the secreted, trimeric
TNF form. In contrast, LT-a polypeptides are secreted in
the lumen of the endoplasmic reticulum concomitantly
with cleavage of the signal sequence. Membrane retention
of TNF was shown to be crucial for the induction of TNF/
LT-a resistance and downmodulation of the cell-surface
TNF receptor (Decoster et al., 1998). Moreover, we had al-
ready demonstrated previously that a functional interac-
tion between TNF and TNF receptor is required to that
end; expression of a biological inactive mutein with
strongly reduced TNF receptor-binding capacity could in-
deed not induce TNF receptor downmodulation nor TNF
resistance (Vanhaesebroeck et al., 1992).
To confirm the hypothesis that membrane retention of
hLT-a is sufficient to downmodulate TNF/LT-a receptor
expression and to induce resistance to the cytotoxic effect
of exogenous TNF or LT-a, we analyzed the effect of ex-
pression of a CHL.hLT-a fusion gene. Like TNF, CHL is a
type-II, trimeric transmembrane protein and the CHL
membrane anchor allows trimerization of the extracellular
domains. Expression of this CHL.hLT-a gene gave rise to
both a membrane-bound and a secreted form of hLT-a, a
feature characteristic of TNF synthesis. CHL.hLT-a trans-
fectants exhibited TNF/LT-a resistance and showed down-
modulation of TNF-R55, but not of TNF-R75. This is con-
sistent with the fact that hLT-a can only interact with
mTNF-R55 and not with mTNF-R75 (Lewis et al., 1991).
The data obtained with CHL.hLT-a are in contrast with
the results for hLT-a, expressed as a secreted protein, and
are analogous to the results obtained with hTNF. Thus the
inability of LT-a to induce TNF/LT-a resistance and
downmodulation of the TNF/LT-a receptor is unambigu-
ously explained by the absence of membrane retention of
LT-a during processing for secretion.
It is remarkable that the mammalian genome codes for
two closely related cytokines, i.e., TNF and LT-a, which
have different biological functions and which are synthe-
sized and processed by a different mechanism. The results
here described illuminate some implications of this differ-
ence. First, our data suggest a possible dual biological role
of membrane-bound TNF. The latter, produced by differ-
ent cell types, such as macrophages, some T cells and some
tumor cells, leads to primarily local inflammatory and/or
immune reactions; but it is also involved in downmodula-
tion of the TNF receptor, hence avoiding that TNF-pro-
ducing cells become a target of their own product (Fiers,
1993). Second, the different effect observed for autocrine-
produced TNF and LT-a might possibly explain why some
cell types, such as HL-60, produce both TNF and LT-a; in-
deed, autocrine TNF downregulates the TNF/LT-a recep-
tors and avoids counterselection. Third, tumor cells ex-
pressing TNF may have been selected to do so in order to
avoid negative effects by TNF (or LT-a) released as an in-
flammatory/immune response of the host. Fourth, our ob-
servations might also partially explain why LT-a is mainly
produced by cells of lymphoid origin, since such cells ei-
ther also express TNF or are devoid of TNF-R55 receptors
(Fiers et al., 1986; Beyaert and Fiers, 1998). Finally, it is
quite possible that the production of LT-a during devel-
opment corresponds mainly to formation of membrane-
bound LT-a/LT-b complexes.
In summary, the observation that in contrast to LT-a,
TNF expression protects L929 against TNF/LT-a—medi-
ated cytotoxicity, is explained by the different pathway of
processing of TNF and LT-a for secretion. Production of
TNF or, as shown in this paper, of hLT-a as a membrane-
bound form allows the producer cells to downmodulate
TNF-R55 (and TNF-R75, depending on the ligand), such
that they become unresponsive to their own product. This
essential role of membrane anchoring is further supported
by the fact that production of secreted TNF after substitu-
tion of the presequence for the signal sequence of IL-6 did
not induce TNF resistance and downmodulation of the
TNF receptors on the cell surface (Decoster et al., 1998),
while membrane anchoring of LT-a in a similar construct
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as TNF did result in receptor downmodulation and resis-
tance.
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